GW Pharmaceuticals to supply MS drug Sativex to Novartis

GW Pharmaceuticals has entered into an exclusive licence agreement for Novartis Pharma AG to commercialise the Sativex drug in Australia, New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) and Africa.

Under the terms of the agreement, Novartis will have exclusive commercialisation rights to Sativex and will also be responsible for regulatory filings and act as Marketing Authorisation holder for Sativex.

GW will be responsible for the manufacture and supply of Sativex to Novartis.

Sativex is a cannabis-based drug that has been developed as a treatment for spasticity due to Multiple Sclerosis (MS).